MARKET

ENLV

ENLV

Enlivex Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.19
-0.15
-1.80%
Closed 16:00 11/15 EST
OPEN
8.43
PREV CLOSE
8.34
HIGH
8.65
LOW
8.15
VOLUME
22.32K
TURNOVER
--
52 WEEK HIGH
44.90
52 WEEK LOW
6.19
MARKET CAP
82.83M
P/E (TTM)
-0.6961
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ENLV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

EPS

ENLV News

  • Enlivex Therapeutics To Present At The 10th Annual Jefferies 2019 London Healthcare Conference
  • GlobeNewswire.3d ago
  • Company News For Nov 5, 2019
  • Zacks.11/05 13:42
  • Enlivex up 38% premarket on encouraging Allocetra data
  • Seeking Alpha - Article.11/04 14:14
  • NIO, RACE among premarket gainers
  • Seeking Alpha - Article.11/04 14:12

More

Industry

Biotechnology & Medical Research
+1.35%
Pharmaceuticals & Medical Research
+1.27%

Hot Stocks

Name
Price
%Change

About ENLV

Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.
More

Webull offers Enlivex Therapeutics Ltd (ENLV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.